Orthopedic medtech company Smith+Nephew reported nearly $1.6 billion in revenue during the second quarter of 2026, according to an Aug. 4 financial report.
Here are 10 things to know:
- Smith+Nephew adjusted its anticipated full-year revenue growth from about 6% to about 4%, with second-half revenue growth expected to be about 5%.
- The company is projecting continued momentum in its sports medicine, advanced wound management and orthopedic sectors.
- The U.S. accounted for $816 million of Smith+Nephew’s $1.6 billion second-quarter revenue.
- Orthopedic revenue in the second quarter of 2026 was $614 million, a slight decrease from $615 million in the second quarter of 2025.
- U.S. knee implants revenue declined 7.2% in the quarter, and U.S. hip implants revenue dropped 1.5%.
- According to Deepak Nath, the company’s CEO, U.S. hip implant revenue experienced “temporary headwinds” and U.S. knee implant revenue had “ongoing challenges” related to new product introductions.
- Smith+Nephew is planning to launch its new kinematic LANDMARK Knee System, with the cementless version expected in the third quarter of 2026.
- The company reported $3.1 billion in revenue and $2.2 billion in gross profit during the first half of 2026.
- Despite declines in implant revenue, the company recorded a trading profit of $566 million.
- In May 2026, Smith+Nephew announced a $500 million share buyback program. As of Aug. 3, the company had settled $216 million in buybacks.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.